Venus Remedies Ltd.

₹1,650.2

25 (1.5%)

VENUSREM Share Price

Pharmaceuticals & Biotechnology

As on September 9, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 2,165 Cr

P/E Ratio21.13

Dividend Yield0.06 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	1,668.22	Bearish
10-DMA	1,645.13	Bullish
20-DMA	1,690.52	Bearish
50-DMA	1,673.99	Bearish
100-DMA	1,495.86	Bullish
200-DMA	1,142.82	Bullish

Historical Performance

1 Year

249.8%

3 Years

598.6%

5 Years

230.2%

10 Years

1471.8%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	7,696	6,529	6,014	5,555	6,002
Total Expenditure	6,223	5,844	5,418	4,955	5,381
Other Income	126	159	116	103	83
Operating Profit	1,599	845	712	703	704
Interest	---	1	1	1	5
Depreciation	257	225	264	323	335
Profit Before Tax	1,342	718	446	379	364
Consolidated Net Profit	1,028	453	285	266	407
Adjusted EPS	77	34	21	20	30

Compounded Sales Growth

10 Years:13

5 Years:7

3 Years:6.7

TTM:3.3

Compounded Profit Growth

10 Years:127.2

5 Years:10.7

3 Years:31.1

TTM:17.8

Stock Price CAGR

10 Years:32.3

5 Years:27

3 Years:92.1

TTM:263.8

Return on Equity

10 Years:-13.8

5 Years:30.5

3 Years:21.3

last year:76.9

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	134	134	134	134	134
Total Reserves	6,504	5,476	4,742	4,470	4,271
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	282	185	599	582	460
Other Current Liabilities	439	367	225	272	378
Short Term Borrowings	---	17	26	36	41
Total Liabilities	8,537	7,157	6,268	6,011	5,791
Capital Work in Progress	514	264	211	261	252
Long Term Loans & Advances	68	50	232	340	334
Currents Investments	738	293	191	201	---
Short Term Loans and Advances	549	655	619	499	584
Total Current Assets	3,952	3,969	3,595	3,228	2,780
Total Assets	8,537	7,157	6,268	6,011	5,791
Adjusted Book Value	497	420	365	344	330

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 21.13, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a strong 3-year price CAGR of 90.8%, indicating sustained price appreciation.
The stock carries a beta of 0.9, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹1599 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹7696 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 3635202.1

No. of Shares: 2203 (Approx)

Performance:263.5%

2635202.1

NIFTY Performance: -6.2%

1 day Top Gainers